Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia
Generalizing about the cost-effectiveness of newborn screening (NBS) is difficult due to the heterogeneity of disorders included in NBS panels, along with data limitations. Furthermore, it is unclear to what extent evidence about cost-effectiveness should influence decisions to screen for specific d...
Main Authors: | Scott D. Grosse, Guy Van Vliet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Neonatal Screening |
Subjects: | |
Online Access: | https://www.mdpi.com/2409-515X/6/4/82 |
Similar Items
-
Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy
by: Patrice K. Held, et al.
Published: (2020-08-01) -
Impact of Newborn Screening on Clinical Presentation of Congenital Adrenal Hyperplasia
by: Rūta Navardauskaitė, et al.
Published: (2021-09-01) -
Landscape of Congenital Adrenal Hyperplasia Newborn Screening in the United States
by: Sari Edelman, et al.
Published: (2020-08-01) -
A three-year follow-up of congenital adrenal hyperplasia newborn screening
by: Isabela L. Pezzuti, et al.
Published: (2014-05-01) -
Devastating salt‐wasting crisis in a four‐month‐old male child with congenital adrenal hyperplasia, highlighting the essence of neonatal screening
by: Nagaspurthy Anugu Reddy, et al.
Published: (2022-07-01)